NASDAQ:CRBP Corbus Pharmaceuticals - CRBP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.17 0.00 (0.00%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.17▼$0.1950-Day Range$0.11▼$0.1952-Week Range$0.10▼$0.62Volume1.95 million shsAverage Volume1.51 million shsMarket Capitalization$21.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Corbus Pharmaceuticals MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.51% of Float Sold ShortDividend StrengthN/ASustainability-0.65Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.64 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Corbus Pharmaceuticals. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.51% of the float of Corbus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorbus Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Corbus Pharmaceuticals has recently decreased by 14.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCorbus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorbus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCorbus Pharmaceuticals has received a 73.92% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Corbus Pharmaceuticals is -0.65. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Corbus Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest16 people have searched for CRBP on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corbus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.20% of the stock of Corbus Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 18.65% of the stock of Corbus Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Corbus Pharmaceuticals are expected to remain at ($0.28) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corbus Pharmaceuticals is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corbus Pharmaceuticals is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorbus Pharmaceuticals has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Corbus Pharmaceuticals (NASDAQ:CRBP) StockCorbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.Read More Receive CRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRBP Stock News HeadlinesFebruary 5, 2023 | americanbankingnews.comCorbus Pharmaceuticals (NASDAQ:CRBP) Now Covered by Analysts at StockNews.comJanuary 31, 2023 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock rises Tuesday, outperforms marketFebruary 5, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 28, 2023 | americanbankingnews.comCorbus Pharmaceuticals (NASDAQ:CRBP) Receives New Coverage from Analysts at StockNews.comJanuary 24, 2023 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock remains steady Tuesday, still outperforms marketDecember 15, 2022 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock rises Thursday, outperforms marketDecember 14, 2022 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock falls Wednesday, underperforms marketNovember 10, 2022 | finance.yahoo.comCorbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingFebruary 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...November 8, 2022 | finance.yahoo.comCorbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 25, 2022 | msn.comWhy Qualtrics International Shares Are Trading Sharply Higher; Here Are 23 Stocks Moving PremarketOctober 14, 2022 | finance.yahoo.comCorbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingSeptember 26, 2022 | finance.yahoo.comCorbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of DirectorsSeptember 22, 2022 | finance.yahoo.comCorbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual ConferenceSeptember 12, 2022 | finance.yahoo.comCorbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 9, 2022 | finance.yahoo.comCorbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateAugust 6, 2022 | finance.yahoo.comCorbus Pharmaceuticals Holdings, Inc. (CRBP)May 10, 2022 | apnews.comCorbus Pharmaceuticals: Q1 Earnings SnapshotMay 10, 2022 | seekingalpha.comCorbus Pharmaceuticals GAAP EPS of -$0.08 beats by $0.01May 10, 2022 | markets.businessinsider.comCorbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateApril 18, 2022 | msn.comMarijuana Stock Movers For April 18, 2022April 8, 2022 | finance.yahoo.comCorbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual MeetingApril 7, 2022 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitorsApril 7, 2022 | msn.comCitius (CTXR) Posts Top-Line Data From Pivotal Lymphoma StudyApril 5, 2022 | msn.comCannabis Stock Gainers And Losers From April 5, 2022April 4, 2022 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock falls Monday, underperforms marketMarch 11, 2022 | finance.yahoo.comCorbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRBP Company Calendar Last Earnings11/08/2022Today2/05/2023Next Earnings (Estimated)3/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRBP CUSIPN/A CIK1595097 Webwww.corbuspharma.com Phone(617) 963-0100Fax617-663-6085Employees41Year Founded2009Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,640,000.00 Net MarginsN/A Pretax Margin-36,209.27% Return on Equity-66.27% Return on Assets-40.89% Debt Debt-to-Equity Ratio0.22 Current Ratio3.86 Quick Ratio3.86 Sales & Book Value Annual Sales$880,000.00 Price / Sales24.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book0.31Miscellaneous Outstanding Shares125,280,000Free Float115,008,000Market Cap$21.49 million OptionableOptionable Beta2.14 Social Links Key ExecutivesYuval CohenChief Executive Officer & DirectorCraig MillianChief Operating OfficerSean F. MoranChief Financial & Accounting OfficerRachael BrakeChief Scientific OfficerBrian WalshVice President-Corporate DevelopmentKey CompetitorsIMVNASDAQ:IMVForte BiosciencesNASDAQ:FBRXPasithea TherapeuticsNASDAQ:KTTAAngion BiomedicaNASDAQ:ANGNTempest TherapeuticsNASDAQ:TPSTView All CompetitorsInsiders & InstitutionsPinnacle Associates Ltd.Sold 95,890 shares on 1/25/2023Ownership: 0.584%ETF Managers Group LLCSold 2,352,166 shares on 11/15/2022Ownership: 3.760%Vanguard Group Inc.Sold 245,408 shares on 11/15/2022Ownership: 3.230%Renaissance Technologies LLCSold 836,329 shares on 11/14/2022Ownership: 0.631%ExodusPoint Capital Management LPBought 362,544 shares on 11/10/2022Ownership: 0.289%View All Insider TransactionsView All Institutional Transactions CRBP Stock - Frequently Asked Questions How have CRBP shares performed in 2023? Corbus Pharmaceuticals' stock was trading at $0.1105 at the beginning of the year. Since then, CRBP stock has increased by 55.2% and is now trading at $0.1715. View the best growth stocks for 2023 here. When is Corbus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023. View our CRBP earnings forecast. How were Corbus Pharmaceuticals' earnings last quarter? Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its quarterly earnings results on Tuesday, November, 8th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.01. What other stocks do shareholders of Corbus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB). What is Corbus Pharmaceuticals' stock symbol? Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP." Who are Corbus Pharmaceuticals' major shareholders? Corbus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.58%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Barbara White, Craig Stuart Millian, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View institutional ownership trends. How do I buy shares of Corbus Pharmaceuticals? Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Corbus Pharmaceuticals' stock price today? One share of CRBP stock can currently be purchased for approximately $0.17. How much money does Corbus Pharmaceuticals make? Corbus Pharmaceuticals (NASDAQ:CRBP) has a market capitalization of $21.49 million and generates $880,000.00 in revenue each year. The biopharmaceutical company earns $-45,640,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. How can I contact Corbus Pharmaceuticals? Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The official website for the company is www.corbuspharma.com. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at ir@corbuspharma.com, or via fax at 617-663-6085. This page (NASDAQ:CRBP) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.